This bill mandates that insurance policies, contracts, or plans providing third-party payment or prepayment for health or medical expenses must include coverage for prescription drugs specifically used to treat metastatic cancer and associated conditions. It defines key terms such as "prescription cancer drug," which refers to drugs used for treating metastatic cancer, and "associated conditions," which are symptoms or side effects related to metastatic cancer treatment. The bill stipulates that coverage for these prescription cancer drugs must be provided without imposing a step therapy protocol, meaning that patients cannot be required to try other medications before receiving the prescribed cancer drug, provided that the drug is FDA-approved and supported by medical standards and peer-reviewed literature.

The bill applies to various classes of third-party payment provider contracts, including individual and group accident and sickness insurance, hospital or medical service contracts, health maintenance organization contracts, and plans for public employees, effective from January 1, 2026. However, it excludes certain types of insurance, such as accident-only, specified disease, and dental or vision coverage. Additionally, the commissioner of insurance is authorized to adopt rules to facilitate the administration of this section.